Posted on

MindMed to Participate in March Investor Conferences

MindMed to Participate in March Investor Conferences

NEW YORK, March 9, 2022 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Robert Barrow, Chief Executive Officer and Director, will participate in the following upcoming investor conferences in March:

34th Annual Roth Conference

Format: Panel – Psychedelics: “Immunotherapy” for the Mind

Date: Tuesday, March 15 at 10:00 AM PST / 1:00 PM EST

Webcast Link: Click Here 

Oppenheimer Virtual Annual Healthcare Conference

Format: Corporate Presentation

Date: Thursday, March 17 at 12:40 PM EST

Webcast Link: Click Here 

Maxim Virtual Growth Conference

Format: Corporate Presentation

Date: March 28-30, 2022

Further Info: Click Here

A replay of the webcasts will be available in the “Investors” section of MindMed’s website for 30 days following each of the presentations.

About MindMed

MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

For Investors: ir@mindmed.co

For Media: media@mindmed.co

Posted on

LSD and psilocybin have the same effects, apparently

MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects

MindMed’s latest study compared the experiences of LSD and psilocybin in high and low doses. 

Subjects were assessed on a scale that measures changes in consciousness like feelings of unity and bliss, ego dissolution, auditory and visual sensations, spiritual experiences, and insightfulness.

Researchers found “no evidence of qualitative differences in altered states of consciousness”  between the substances, except that LSD lasted longer. Any other differences could be attributed to the dose, not the substance.

They found that 20 mg psilocybin is equivalent to 100 µg LSD (a 1:200 ratio), and that body weight had no influence on the concentration of the drugs in blood plasma.

Posted on

MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

– Automatic conversion to be effective March 14, 2022 –

NEW YORK, February 23, 2022 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced today  that all the Company’s issued and outstanding multiple voting shares (the “Multiple Voting Shares”) will undergo a mandatory conversion into subordinate voting shares (the “Subordinate Voting Shares”) (the “Conversion”), in accordance with the Company’s Articles. The Conversion will be effective March 14, 2022 (the “Effective Date”). 

The Company’s transfer agent will provide requisite notice to each holder of Multiple Voting Shares (the “MVS Holders”). On the Effective Date, the Multiple Voting Shares will automatically, without any action on the part of MVS Holders, be converted into Subordinate Voting Shares on the basis of one Multiple Voting Share for 100 Subordinate Voting Shares, and in the case of fractions of Multiple Voting Shares, such number of Subordinate Voting Shares as is determined by multiplying the fraction by 100.

Pursuant to the Conversion, there will be no Multiple Voting Shares issued and outstanding, and the Company will have a single class of shares, the Subordinate Voting Shares, issued and outstanding. 

“This conversion reflects an important step that solidifies our transformation into a primarily U.S. based company, and an opportunity to simplify our capitalization structure for the benefit of existing and new shareholders,” said Robert Barrow, Chief Executive Officer and Director of MindMed. “We are rapidly maturing and look forward to providing additional updates on our progress as we continue to drive our business and the psychedelic industry forward.” 

About MindMed

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

Forward-Looking Statements

Certain statements in this news release related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described under the headings “Risk Factors” in the Company’s filings with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company’s profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov.

For Media: media@mindmed.co

For Investors: ir@mindmed.co

Posted on

Clearmind Medicine to Host a “Psychedelics for Alcoholism” Event for Investors on February 23

Clearmind Medicine to Host a “Psychedelics for Alcoholism” Event for Investors on February 23

Market analyst Marissa Wright discusses the psychedelics market with a focus on psychedelic treatments for alcohol use disorder

TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE)– Clearmind Medicine Inc. (CSE: CMND, FSE:CWY0, OTC Pink: CMNDF)

(“Clearmind” or the “Company“), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announced that as part of its highly attended “Psychedelics for Alcoholism” event series it will host market analyst Marissa Wright at a virtual event for investors. 

The online event will be held on February 23, 2022 at 12 p.m. EST and is open and free to all, Registration is required.

Clearmind’s last webinar attracted more than 1200 viewers.

“Psychedelics for Alcoholism: Investor Deep Dive” will provide investors a broad overview of the psychedelic treatments market with an emphasis on alcohol use disorders.

Wright is a consultant on business strategy, market analysis, and new market entry for global firms. Based in Vancouver, Canada, she has 40 years of experience as an entrepreneur across a wide range of industries in North America and is an active member of Keiretsu Forum, the world’s largest early-stage angel investor network.

‍

“As an innovative public company with a significant IP portfolio operating in an exciting and relatively new market, we want to provide investors a comprehensive review of the psychedelic treatment market and its potential,” said Adi Zuloff-Shani, Ph.D., CEO of Clearmind “The problem of alcoholism is only getting worse, with increased strain from the pandemic. Clearmind is working to bring long overdue relief and a new treatment in unique ways, and we look forward to highlighting some of the major reasons for our decision to pursue alcoholism indication as our first indication.”

The event will be hosted by Shannon Smadella, formerMiss Canada & Spokesperson for World Psychedelics Day, and will feature Adi Zuloff-Shani, PhD, Chief ExecutiveOfficer of Clearmind and Adjunct Prof. Mark Haden, Clearmind’s VP of Business Development.

 To learn more about Psychedelics for Alcoholism, visit the event website.

‍

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of four patent families. The Company intends to seek additional patents for its compounds whenever warranted and willremain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on theCanadian Securities Exchange under the symbol “CMND“, the Frankfurt Stock Exchange under the symbol“CWYO” and on the OTC pink under the symbol “CMNDF“.

For further information, please contact:

Investor Relations

Email: invest@clearmindmedicine.com Telephone: (604) 260-1566

General Inquiries

Info@Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. 

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful.The securities issued, or to be issued, under the PrivatePlacement have not been, and will not be, registered under the UnitedStates Securities Act of 1933, as amended, and may not be offered or sold in the UnitedStates absent registration or an applicable exemption from registration requirements.

Neither the Canadian SecuritiesExchange (the “CSE”) nor its RegulationServices Provider (as that term is defined in the policies of the CSE)accepts responsibility for the adequacy or accuracy of this release.

Posted on

Clearmind Medicine Secures CAD$1.6 Million in Private Placement

Clearmind Medicine Secures CAD$1.6 Million in Private Placement

Clearmind and Medigus, the investor, intend to form a joint venture in the field of food industry, based on Clearmind’s unique psychedelics IP

TORONTO,February 8, 2022– Clearmind Medicine Inc. (CSE:CMND, FSE: CWY0, OTCMKTS: CMNDF)(“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under-treated health problems, announced today it has signed an agreement for a private placement. With gross proceeds to the Company of approximately CAD$1.6 million (or USD$1.25 million),the investment will be made by Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions.

Clearmind and Medigus intend to form a joint venture in the food industry field, based on Clearmind’s unique psychedelics intellectual property (the “IP”). The joint venture expects to focus on the product development of food supplements (the “Products”),on the basis of the IP, as well as obtaining the necessary regulatory approvals to enable the registration and distribution of the Products in certain targeted countries.  

TheCompany will issue Medigus 1,987,344 units (the “Units”) at a subscription price of CAD$0.80 per Unit (the “Subscription Price”).  Each Unit is comprised of one common share  of the Company (each a “CommonShare”) and one Common Share purchase warrant (each, a “Warrant”)exercisable into one additional Common Share at a price per Common Share ofCAD$2.00, exercisable for a period of 18 months from issuance. approximately CAD$960,000of the gross proceeds will be paid for in cash and approximately CAD$640,000 of the gross proceeds (the “Share Exchange Proceeds”) will be satisfied through the issuance to the Company of that number of American DepositoryShares of Medigus arrived at by dividing the Share Exchange Proceeds by US$1.20. Additionally, Medigus will be entitled to 10% of the initial equity of a potential venture in the area of psychedelics, based on a research project currently conducted according to an agreement between the Company and the commercialization arm of a leading Israeli academic institution.  

About Clearmind Medicine Inc. 

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

TheCompany’s intellectual portfolio currently consists of four patent families. TheCompany intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND“, the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC Markets under the symbol “CMNDF“.

For further information, please contact:

Investor Relations,

Email: invest@clearmindmedicine.com

Telephone: (604) 260-1566

General Inquiries,

Info@Clearmindmedicine.com

www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE”)nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Posted on

Clearmind Medicine Now Fully Eligible for Settlement through the Depository Trust Company (“DTC”)

Clearmind Medicine Now Fully Eligible for Settlement through the Depository Trust Company (“DTC”)

TORONTO,January 31, 2022– Clearmind Medicine Inc. (CSE:CMND, FSE: CWY0, OTCMKTS: CMNDF)(“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced that the Company’s common shares are now fully eligible for settlement through the Depository Trust Company (“DTC”), a subsidiary of the Depository Trust & Clearing Corp. which manages the electronic clearing and settlement of publicly-traded companies in the UnitedStates of America.

Clearmind’s common shares are quoted in the United States on the OTC Markets under the ticker symbol “CMNDF”. The combination of DTC eligibility and Clearmind’s OTC listing will provide a more efficient trading process for existing U.S. based Clearmind share holders and potential new investors and potentially increase liquidity in the trading of Clearmind shares.

Through electronic clearing of securities, DTC eligibility significantly reduces the costs and accelerates the settlement process for investors and brokers alike.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.  

The Company’s intellectual portfolio currently consists of four patent families. TheCompany intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND“, the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC Markets under the symbol “CMNDF“.

For further information, please contact:

Investor Relations,

Email: invest@clearmindmedicine.com

Telephone: (604) 260-1566

General Inquiries,

Info@Clearmindmedicine.com

www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. 

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of theCompany shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under thePrivate Placement have not been, and will not be, registered under the UnitedStates Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

‍

Neither the Canadian SecuritiesExchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Posted on

MDMA Passport + Commercial LSD Study: issue 34

Hello and welcome back.

Who else is counting down the days til the Daily Mushroom + Entheon Biomedical Mental Health Town Hall?? If you haven’t registered yet, you can do so here. What are you waiting for? It’s totally free and virtual so anyone can attend.

Here’s what’s in store for you in today’s issue:

🍄 The psychedelic that’s already in our brains

🍄 MAPS receives Innovation Passport for MDMA therapy 🎉

🍄 First commercial study of LSD in 40 years

🍄 Will Oregon legalize microdosing?

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

7 days of tripping to heal mentally, physically and radically change a career path

In this episode of The Daily Mushroom Podcast, we have Cory Firth, Executive Director of The Canadian Psychedelic Association and founder of DoseDay! Cory opens about his battle with mental health and shares his experience with psychedelics in his quest to find meaning in his life. He also talks about how he got himself into a 7 ayahuasca retreat and what that journey gave him.

Therapeutic banner

First commercial study of LSD in 40 years

MindMed’s LSD-based compound received FDA clearance, allowing the company to proceed with a trial that will be the first commercial study of LSD in over 40 years.

The study will assess 200 patients with generalized anxiety disorder to find the optimal dose of the formulation. 

Shares of MNMD spiked 30% following the announcement 💰

Goodbye Blue Mondays

A recent study found pure MDMA administered in a clinic does not have the “come down” effect that recreational users often report the day after dosing. 

Participants maintained a positive mood during the week following the dose. Plus, no participant had used or desired to use illegal MDMA at the 3 month and 6 month follow ups.

Mario’s secret revealed 🍄

The iconic red and white spotted mushroom (officially called Amanita Muscaria and unofficially called the Super Mario mushroom) is showing potential to treat arthritis.

Psyched Wellness (PSYC) is working with the National Research Council of Canada (NRC) to study the mushroom’s properties. It doesn’t contain psilocybin, but has a different psychoactive component called muscimol.

Preliminary data suggests that Amantia Muscaria could reduce inflammation in the skin, gut, brain, and lungs. The company believes it has potential to treat chronic inflammatory conditions like arthritis.

Maybe that’s why Mario can jump so high without destroying his joints 😉

inspirational banner

MAPS receives Innovation Passport for MDMA therapy 🎉

The Innovation Passport will make MDMA therapy for PTSD widely available in the UK, as rapidly as possible!

The Multidisciplinary Association for Psychedelic Studies (MAPS) found that 88% of patients had a reduction in PTSD symptoms after three MDMA sessions in conjunction with trauma-focused therapy. 

The organization was granted an Innovation Passport for the treatment – a UK designation that speeds up the timeline for approval of innovative medicines for life-threatening conditions (similar to Breakthrough Therapy Designations in the US, which the treatment received in 2017).

The psychedelic that’s already in our brains

Did you know that one of the most promising addiction treatments is a psychedelic compound that’s found throughout nature and is present within the human body?

It’s called DMT (N,N-Dimethyltryptamine) and is thought to be produced in the brain’s pineal gland. DMT is released in large amounts when we dream and when we die.  

Learn what leading DMT experts have discovered at the Daily Mushroom + Entheon Biomedical Mental Health Town Hall on Thursday, Feb. 3rd. Register now for free to get the inside scoop 👇

Donating psilocybin to patients in need

CCrest Laboratories is donating psilocybin truffles so patients in need can access the medicine for free through Canada’s Special Access Program (SAP).

The company was just approved as a licensed psilocybin producer by Health Canada, along with Numinus Wellness (NUMI) and Filament Health’s (FH) Psilo Scientific, allowing them to supply psilocybin for clinical trials and emergency treatments through the SAP. 

The truffles will be grown by Red Light Holland (TRUFF) and tested at CCrest Labs before being donated as part of their “compassionate need and free supply” approach.

business banner

Beckley Psytech began training psychotherapists for a phase II study on 5-MeO-DMT for treatment-resistant depression through Fluence’s interactive training program. Within the next year, Beckley aims to train 80 psychotherapists on how to administer psychedelic therapy.

Mydecine (MYCO) is partnering with a UK-based charity called Combat Stress and the King’s College London to study psilocybin therapy as a treatment for veterans with severe, treatment-resistant PTSD. 

Psygen Labs entered into an agreement to supply Universal Ibogaine (IBO) with ibogaine for an upcoming clinical trial on opioid addiction.

atai Life Sciences (ATAI) launched a wholly owned platform company called Invyxis, which will focus on developing novel compounds that target serotonin 5-HT2A receptors.

Akome Biotech, a subsidiary of Core One Labs’ (COOL), signed a consulting agreement with the University of Barcelona to develop psychedelic treatments for depression, stroke, Parkinson’s, and Alzheimer’s.

Ketamine One (MEDI) changed its name to Wellbeing Digital Sciences and partnered with Nova Mentis (NM) to study psilocybin microdosing for fragile x syndrome.

legal banner

Oregon is on track to provide legal psilocybin services in 2023

But one question remains unanswered: will the new program include microdosing?

For the past year, the Oregon Health Authority has been planning the regulatory framework to implement Measure 109, which legalized psilocybin sessions under the care of licensed facilitators. The program is on schedule to roll out at the beginning of 2023.

At the latest public Zoom meeting, a push to include microdosing in the program received backlash from some advisory board members, but others thought it was worth considering. Members have until the end of June to reach a consensus.

 

Two psilocybin bills filed in Oklahoma

The first bill would promote research focused on treating depression and anxiety in veterans. The second would promote research into 10 different conditions and reduce the penalty for psilocybin possession to a fine.

Video of the Week

The Battle Over Psychedelic Therapy’s Future

Playlist of the Week

Trippy Songs 🍄🍃👽🚀
Posted on

Clearmind Medicine Partners with Dr. Gabor Maté to Discuss Alcohol Use Disorder and Trauma in a Special Virtual Event on February 3

Clearmind Medicine Partners with Dr. Gabor Maté to Discuss Alcohol Use Disorder and Trauma in a Special Virtual Event on February 3

A Renowned Speaker, and Bestselling Author, Dr. Gabor Maté is Highly Sought After for His Expertise on a Range of Topics Including Addiction, Stress and Childhood Development

TORONTO, Jan. 28, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the “Company”), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is proud to announce that as part of its “Psychedelics for Alcoholism” events series, it will host Dr. Gabor Maté, to discuss alcohol use disorder and trauma, and how Clearmind’s candidate treatment may create a clear path to dealing with trauma, at a special virtual event.

The online event will be held on February 3, 2022, commencing at 12 p.m. EST, and is open and free to all, registration required.

A renowned speaker, and bestselling author, Dr. Gabor Maté is highly sought after for his expertise on a range of topics including addiction, stress and childhood development. His four books have been translated into nearly thirty languages. Dr. Gabor Maté is a retired Vancouver physician and a member of the Order of Canada. His next work, The Myth Of Normal: Trauma, Illness and Healing in a Toxic Culture, will be published on September 13th 2022, and is available for pre-sale now through (Amazon etc.).

Dr. Adi Zuloff-Shani, Ph.D., CEO of Clearmind, commented on the announcement, “We at Clearmind are committed to creating meaningful collaborations that eventually can benefit the lives of millions of people around the world including the engagement of renowned people in our fields of research.  Partnering with the world-renowned expert, Dr. Gabor Maté, is a tremendous honor. The upcoming event will provide participants with valuable and fascinating insight regarding some of the most common mental health issues prevalent nowadays.”

The event will be hosted by Shannon Smadella, former Miss Canada & Spokesperson for World Psychedelics Day, and will feature Adi Zuloff-Shani, PhD, Chief Executive Officer of Clearmind and Adjunct Prof. Mark Haden, Clearmind’s VP of Business Development.

Clearmind is honored to have numerous companies supporting the event, including Microdose, Psychedelic Newswire, CFN Media, Investor Brand Network, Take Back Your Power, Vallin Hypnotherapy, Insight Global, The Flying Sage, and Force Field EMF.

‍

To learn more about Psychedelics for Alcoholism, visit the event website.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of four patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND”, the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC pink under the symbol “CMNDF”.

For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Posted on

First commercial study of LSD in 40 years

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

MindMed’s LSD-based compound received FDA clearance, allowing the company to proceed with a trial that will be the first commercial study of LSD in over 40 years.

The study will assess 200 patients with generalized anxiety disorder to find the optimal dose of the formulation. 

Shares of MNMD spiked 30% following the announcement 💰

PDF of article

Posted on

Clearmind Medicine to Host “Psychedelics for Alcoholism: From Molecule to Medicine” Virtual Event on January 26

Clearmind Medicine to Host “Psychedelics for Alcoholism: From Molecule to Medicine” Virtual Event on January 26

Clearmind’s Management Team Will Explain the Regulatory Process Required for Clearmind’s Patented MEAI Molecule to Become an FDA Approved Medicine for Treating Alcohol Use Disorder and Binge Drinking

TORONTO, Jan. 19, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the “Company”), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce it will be hosting Psychedelics For Alcoholism, a free, live virtual event highlighting Clearmind’s patented MEAI molecule “From Molecule to Medicine: The Clinical Trial Pathway”.

The online event will be held on January 26, 2022, commencing at 12 p.m. EST, registration is open and free to all.

The event will be hosted by Shannon Smadella, Spokesperson & Business Advisory of World Psychedelic Day, and will feature Adi Zuloff-Shani, PhD, Chief Executive Officer of Clearmind and Adjunct Prof. Mark Haden, Clearmind’s VP of Business Development.

Representatives from the Company will provide an update on Clearmind’s MEAI-based medicines and their potential for the treatment of alcohol use disorder and binge drinking including explaining the process required by the FDA to approve Clearmind’s patented MEAI molecule as a medicine.

To learn more about Psychedelics for Alcoholism, visit the event website.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of four patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND“, the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC pink under the symbol “CMNDF“.

For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.